drugset / Trial / NCT02180334
The Effect of Combination of Mosapride and DPP-4 Inhibitor on Plasma Concentration of Incretin Hormones
Phase 4
Completed
12 enrolled
Seoul National University Hospital
Daewoong Pharmaceutical Co. LTD. · collab
RandomizedCrossoverDouble-blindBasic science
Summary
The aim of this study is to investigate the effects of combined administration of mosapride as modulator of gastrointestinal motility and DPP-4 inhibitor on secretion of gut hormone such as glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP), and oral glucose tolerance. Additionally, change in lipid profile and insulin secretion will be also assessed.
Timeline
- Start
- 2014-07
- Primary completion
- 2014-11
- Completion
- 2015-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mosapride | Small molecule | 5 mg | Oral |
| Background | Acetaminophen | Small molecule | 1500 mg | Oral |
| Background | Linagliptin | Small molecule | 5 mg | Oral |